StockData

Fate Therapeutics vs Innate Pharma

FATE and IPHA side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How FATE and IPHA compare

Fate Therapeutics grew revenue faster over the last twelve months (−33.4% versus −55.2% for Innate Pharma).

Fate Therapeutics scores higher on the StockData Score (6 against 0 for Innate Pharma), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricFATEIPHA
Size and price
Market cap$153M–
Share price$1.28$1.38
Change, 1 year23.1%−28.1%
Change, 5 years−97.7%−72.5%
Beta (5Y)2.420.93
Employees161181
StockData Score
Total score6 (better)0
Valuation score1 (better)0
Growth score00
Performance score00
Health score5 (better)0
Dividend score00
Valuation
P/S32.3×–
P/B1.2×–
FCF yield−69.7%–
Fair value$1.10–
Margin of safety−16.5%–
Growth
Revenue growth (TTM)−33.4% (better)−55.2%
Revenue growth, 5Y average−26.7% (better)−33.6%
Profitability
Operating margin−2760%−600% (better)
Net margin−2620%–
FCF margin−2249%−587% (better)
Return on equity−67.8%–
Return on invested capital−1647%–
Financial health
Debt / equity0.00–
Interest coverage–−17.3×
Current ratio4.41 (better)0.60
Altman Z-score−9.92–
Piotroski F-score3–
Dividends and buybacks
Shareholder yield0.00%–
Ownership
Held by institutions59.9%0.21%
Held by insiders25.7%16.2%
Insider net buying, 12 months−$336K–
Short interest, % of float11.2%–

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.